DURHAM, N.C.--Pfizer Animal Health Global Poultry’s new in ovo
vaccination device, which was officially unveiled at IPE, could help
improve operations at smaller hatcheries, according to one of the
device’s trial participants.
Marciano Régis Tonus, agribusiness director of Frango Seva, in Pato
Branco, Brazil, spent a month trialling the new Embrex® Inovoject® m, a
semi-automated device designed specifically for hatcheries that do not
have the floor space or throughput to accommodate one of the larger,
fully automated Embrex Inovoject devices. Processing greater than
800,000 eggs throughout the trial, Mr Tonus is pleased with the results.
“I believe that all hatcheries handling about the same number of eggs as
this hatchery would be able to use a machine like Inovoject m. It’s
small, easy to use and it’s simple.” Mr Tonus explained that the company
had been using subcutaneous vaccination before trialling the in ovo
technology.
“The most common problem we have with subcutaneous vaccination is due to
the people’s welfare. They sometimes develop health problems because of
the repetition of the subcutaneous injection process. For example,
problems in their arms because of the position they have to adopt for
the process,” he said.
Speaking at the launch meeting in Atlanta, Melinda Freson, Senior
Manager, Global BioDevices, at Pfizer Global Poultry, said the new
device was developed in response to market needs: “In ovo vaccination
has a number of advantages over subcutaneous vaccination on day of
hatch: it provides the earliest possible immunity against disease
challenge, it is accurate and reliable, less stressful for chicks, less
labor intensive and allows quicker delivery of chicks to the grow-out
environment. Until now, these advantages have only been available to the
larger producers.”
Said Mr Tonus, Inovoject m is able to reduce the distance between the
small companies and the big companies in Brazil by giving them an
opportunity to use new technology.
According to Ms Freson, Inovoject m is likely to attract particular
attention from producers in emerging markets who want to improve
operational efficiencies in addition to the quality of the end product.
“We have conducted a number of trials around the world in
differentdevice configurations and the reaction has been very positive,”
explained Ms Freson.
Inovoject m can handle between 12,000 and 20,000 eggs per hour and
includes the same injection technology that has made Embrex Inovoject
the leading name in commercial in ovo vaccination worldwide. Each
Inovoject m is available with the world-renowned Embrex service model.
Mr Tonus stated, “I am really happy that Pfizer asked us to do the trial
and we are doing our best to create a good environment in the hatchery
and in the field. They are doing their best to help us get the best
possible results in the field.
###
About Pfizer Animal Health Global Poultry
Pfizer Animal Health Global Poultry is a leading provider of innovative,
high-performance poultry health solutions to the global poultry industry.
Pfizer Global Poultry is committed to delivering reliable products
combined with world-class customer service that the global poultry
industry has grown to depend on to enhance bird performance and improve
poultry operations. For more information about Pfizer Global Poultry
visit www.pfizerglobalpoultry.com
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc., is a world leader
in the discovery, development and manufacture of innovative animal
health vaccines, medicines, diagnostic products and genetic tests.
Pfizer Animal Health invests more in research and development than any
other animal health company. We work to assure a safe, sustainable
global food supply from healthy beef and dairy cattle, swine, poultry,
sheep and fish while helping dogs, cats and horses live healthier longer
lives. We strive to be the animal health company that provides full
healthcare solutions to veterinarians, livestock producers, and pet
owners. To learn more, visit https://animalhealth.pfizer.com.
All brands are the property of Pfizer. ©2012 Pfizer Inc. All rights
reserved.
Pfizer Media Contact:
Jessica Rasmussen
+1 919-410-9670
Jessica.rasmussen@pfizer.com
or
Issued by:
Garnett Keeler PR
Mike Keeler
+44 (0)20 8647 4467
mike.keeler@garnettkeeler.com